Literature DB >> 21884675

Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.

Alexander Burashnikov1, Alyssa Petroski, Dan Hu, Hector Barajas-Martinez, Charles Antzelevitch.   

Abstract

BACKGROUND: Wenxin Keli is a Chinese herb extract reported to be of benefit in the treatment of cardiac arrhythmias, cardiac inflammation, and heart failure. METHODS AND
RESULTS: We evaluated the electrophysiologic effects of Wenxin Keli in isolated canine arterially perfused right atrial preparations with a rim of right ventricular tissue (n = 11). Transmembrane action potentials and a pseudoelectrocardiogram were simultaneously recorded. Acetylcholine (1 μM) was used to induce atrial fibrillation (AF) and to test the anti-AF potential of Wenxin Keli (5 g/L). Wenxin Keli produced preferential abbreviation of action potential duration measured at 90% repolarization (APD(90)) in atria, but caused atrial-selective prolongation of the effective refractory period, due to the development of postrepolarization refractoriness. The maximum rate of rise of the action potential upstroke was preferentially reduced in atria. The diastolic threshold of excitation increased in both atria and ventricles, but much more in atria. The duration of the "P wave" (index of atrial conduction time) was prolonged to a much greater extent than the duration of the "QRS complex" (index of ventricular conduction time). Wenxin Keli significantly reduced I(Na) and shifted steady-state inactivation to more negative potentials in HEK293 cells stably expressing SCN5A. Wenxin Keli prevented the induction of persistent AF in 100% atria (6/6) and, in another experimental series, was found to terminate persistent acetylcholine-mediated AF in 100% of atria (3/3).
CONCLUSION: Wenxin Keli produces atrial-selective depression of I(Na)-dependent parameters in canine isolated coronary-perfused preparations via a unique mechanism and is effective in suppressing AF and preventing its induction, with minimal effects on the ventricular electrophysiology.
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884675      PMCID: PMC3236802          DOI: 10.1016/j.hrthm.2011.08.027

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  24 in total

1.  Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs.

Authors:  Sandeep V Pandit; Sharon Zlochiver; David Filgueiras-Rama; Sergey Mironov; Masatoshi Yamazaki; Steven R Ennis; Sami F Noujaim; Antony J Workman; Omer Berenfeld; Jerome Kalifa; José Jalife
Journal:  Cardiovasc Res       Date:  2010-11-13       Impact factor: 10.787

2.  Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction.

Authors:  Dan Hu; Sami Viskin; Antonio Oliva; Tabitha Carrier; Jonathan M Cordeiro; Hector Barajas-Martinez; Yuesheng Wu; Elena Burashnikov; Serge Sicouri; Ramon Brugada; Rafael Rosso; Alejandra Guerchicoff; Guido D Pollevick; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2007-04-10       Impact factor: 6.343

Review 3.  Amiodarone for atrial fibrillation.

Authors:  Peter Zimetbaum
Journal:  N Engl J Med       Date:  2007-03-01       Impact factor: 91.245

4.  AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.

Authors:  Alexander Burashnikov; Andrew C Zygmunt; Jose M Di Diego; Gunilla Linhardt; Leif Carlsson; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2010-07       Impact factor: 3.105

5.  Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block.

Authors:  Andrew C Zygmunt; Vladislav V Nesterenko; Sridharan Rajamani; Dan Hu; Hector Barajas-Martinez; Luiz Belardinelli; Charles Antzelevitch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-05       Impact factor: 4.733

6.  Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

Authors:  Alexander Burashnikov; Serge Sicouri; José M Di Diego; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2010-10-05       Impact factor: 24.094

Review 7.  Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.

Authors:  Ursula Ravens; Erich Wettwer
Journal:  Cardiovasc Res       Date:  2010-12-15       Impact factor: 10.787

Review 8.  Innovative approaches to anti-arrhythmic drug therapy.

Authors:  Stanley Nattel; Leif Carlsson
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

9.  Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.

Authors:  Kapil Kumar; Bruce D Nearing; Marcelo Carvas; Bruno C G Nascimento; Mariana Acar; Luiz Belardinelli; Richard L Verrier
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

10.  Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Aaron Glass; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-03-21       Impact factor: 6.343

View more
  35 in total

Review 1.  Role of late sodium channel current block in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

2.  Effect of berberine on acetylcholine-induced atrial fibrillation in rabbit.

Authors:  Zhi-Wen Zhou; Hong-Chao Zheng; Li-Fang Zhao; Wei Li; Jian-Wen Hou; Yi Yu; Pi-Zhi Miao; Jian-Ming Zhu
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

Review 3.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 4.  J-wave syndromes: Brugada and early repolarization syndromes.

Authors:  Charles Antzelevitch; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2015-04-11       Impact factor: 6.343

5.  Novel Therapeutic Strategies for the Management of Ventricular Arrhythmias Associated with the Brugada Syndrome.

Authors:  Bence Patocskai; Charles Antzelevitch
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-13       Impact factor: 0.694

Review 6.  Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture, biofeedback and more.

Authors:  Arun Kanmanthareddy; Madhu Reddy; Gopi Ponnaganti; Hari Priya Sanjani; Sandeep Koripalli; Nivedita Adabala; Avanija Buddam; Pramod Janga; Thanmay Lakkireddy; Sudharani Bommana; Ajay Vallakati; Donita Atkins; Dhanunjaya Lakkireddy
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

7.  Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome.

Authors:  Yoshino Minoura; Brian K Panama; Vladislav V Nesterenko; Matthew Betzenhauser; Hector Barajas-Martínez; Dan Hu; José M Di Diego; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2013-03-14       Impact factor: 6.343

Review 8.  Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects.

Authors:  Charles Antzelevitch; Bence Patocskai
Journal:  Curr Probl Cardiol       Date:  2015-06-11       Impact factor: 5.200

9.  Wenxin Keli suppresses atrial substrate remodelling after epicardial ganglionic plexi ablation.

Authors:  Jinping Xiao; Qingyan Zhao; A Hafid Kebbati; Hongping Deng; Xule Wang; Zixuan Dai; Shengbo Yu; Congxin Huang
Journal:  Exp Clin Cardiol       Date:  2013

Review 10.  Pharmacological Therapy in Brugada Syndrome.

Authors:  Oholi Tovia Brodie; Yoav Michowitz; Bernard Belhassen
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.